Next-generation sequencing: a transformative tool for vaccinology.

摘要

Next-generation sequencing (NGS) has revolutionized the fields of basic and clinical research in the 5 years since its introduction to the scientific community. Current NGS platforms on the market such as Roche 454 (Roche, CT, USA), Genome Analyzer (Illumina/Solexa, CA, USA), SOLiD~(TM) (Applied Biosystems [ABI], CA, USA) and Heliscope~(TM) (Helicos Biosciences, MA, USA) share one common attribute: highly parallel sequencing of DNA molecules to generate sequence outputs on an order of magnitude of 0.5 to greater than 40 Gb per sequencing run, thus enabling researchers to design experiments that were previously beyond the realms of feasibility and affordability [1-5]. The genotypic information obtained using these high-throughput systems allows the in-depth understanding of genotype-phenotype associations, critical to the development of the field of personalized medicine.